1. Home
  2. EE vs ANAB Comparison

EE vs ANAB Comparison

Compare EE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Excelerate Energy Inc.

EE

Excelerate Energy Inc.

HOLD

Current Price

$39.08

Market Cap

1.2B

Sector

Utilities

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$53.32

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EE
ANAB
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
EE
ANAB
Price
$39.08
$53.32
Analyst Decision
Buy
Buy
Analyst Count
5
12
Target Price
$39.20
$71.67
AVG Volume (30 Days)
252.5K
746.0K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
0.96%
N/A
EPS Growth
0.79
91.02
EPS
0.37
N/A
Revenue
$1,228,263,000.00
$234,603,000.00
Revenue This Year
$23.59
N/A
Revenue Next Year
$24.37
$52.14
P/E Ratio
$106.14
N/A
Revenue Growth
44.26
157.01
52 Week Low
$21.29
$17.11
52 Week High
$43.18
$73.30

Technical Indicators

Market Signals
Indicator
EE
ANAB
Relative Strength Index (RSI) 58.30 43.85
Support Level $31.76 $51.67
Resistance Level $40.18 $57.70
Average True Range (ATR) 1.27 3.62
MACD -0.16 -0.35
Stochastic Oscillator 61.90 33.59

Price Performance

Historical Comparison
EE
ANAB

About EE Excelerate Energy Inc.

Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: